SOTERA HEALTH COMPANY Operating Income
SOTERA HEALTH COMPANY (SHC) reported Operating Income of $297.63 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2025-02-27
- SOTERA HEALTH COMPANY operating income (loss) for the quarter ending 2024-12-31 was $87.15M, a 16.23% decline year-over-year.
- SOTERA HEALTH COMPANY operating income (loss) for the quarter ending 2024-09-30 was $80.51M, a 5.79% increase year-over-year.
- SOTERA HEALTH COMPANY operating income (loss) for the quarter ending 2024-06-30 was $76.80M, a 21.51% increase year-over-year.
- SOTERA HEALTH COMPANY operating income (loss) for the quarter ending 2024-03-31 was $53.17M, a 59.37% increase year-over-year.
- SOTERA HEALTH COMPANY operating income (loss) for fiscal 2024 was $297.63M, a 7.57% increase from fiscal 2023.
- SOTERA HEALTH COMPANY operating income (loss) for fiscal 2023 was $276.69M, a 11.41% increase from fiscal 2022.
- SOTERA HEALTH COMPANY operating income (loss) for fiscal 2022 was $248.35M, a 3.27% decline from fiscal 2021.
- SOTERA HEALTH COMPANY operating income (loss) for fiscal 2021 was $256.73M, a 24.62% increase from fiscal 2020.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $87.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $167.65M derived: sum of 2 quarters · filed 2025-02-27 | $244.45M derived: sum of 3 quarters · filed 2025-02-27 | $297.63M 10-K · filed 2025-02-27 |
| 2024-09-30 | $80.51M 10-Q · filed 2024-11-05 | $157.31M derived: sum of 2 quarters · filed 2024-11-05 | $210.48M 10-Q · filed 2024-11-05 | $314.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $76.80M 10-Q · filed 2024-08-05 | $129.97M 10-Q · filed 2024-08-05 | $234.00M derived: sum of 3 quarters · filed 2025-02-27 | $310.10M derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $53.17M 10-Q · filed 2024-05-02 | $157.20M derived: sum of 2 quarters · filed 2025-02-27 | $233.30M derived: sum of 3 quarters · filed 2025-02-27 | $296.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $104.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $180.12M derived: sum of 2 quarters · filed 2025-02-27 | $243.33M derived: sum of 3 quarters · filed 2025-02-27 | $276.69M 10-K · filed 2025-02-27 |
| 2023-09-30 | $76.10M 10-Q · filed 2024-11-05 | $139.30M derived: sum of 2 quarters · filed 2024-11-05 | $172.67M 10-Q · filed 2024-11-05 | $232.84M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $63.20M 10-Q · filed 2024-08-05 | $96.57M 10-Q · filed 2024-08-05 | $156.74M derived: sum of 3 quarters · filed 2025-02-27 | $219.93M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $33.37M 10-Q · filed 2024-05-02 | $93.53M derived: sum of 2 quarters · filed 2025-02-27 | $156.73M derived: sum of 3 quarters · filed 2025-02-27 | $228.22M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $60.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $123.36M derived: sum of 2 quarters · filed 2025-02-27 | $194.86M derived: sum of 3 quarters · filed 2025-02-27 | $248.35M 10-K · filed 2025-02-27 |
| 2022-09-30 | $63.20M 10-Q · filed 2023-11-01 | $134.69M derived: sum of 2 quarters · filed 2023-11-01 | $188.18M 10-Q · filed 2023-11-01 | $254.61M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $71.50M 10-Q · filed 2023-08-03 | $124.99M 10-Q · filed 2023-08-03 | $191.41M derived: sum of 3 quarters · filed 2024-02-27 | $257.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $53.49M 10-Q · filed 2023-05-03 | $119.92M derived: sum of 2 quarters · filed 2024-02-27 | $185.59M derived: sum of 3 quarters · filed 2024-02-27 | $263.86M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $66.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $132.10M derived: sum of 2 quarters · filed 2024-02-27 | $210.37M derived: sum of 3 quarters · filed 2024-02-27 | $256.73M 10-K · filed 2024-02-27 |
| 2021-09-30 | $65.67M 10-Q · filed 2022-11-02 | $143.94M derived: sum of 2 quarters · filed 2022-11-02 | $190.31M 10-Q · filed 2022-11-02 | $242.69M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $78.27M 10-Q · filed 2022-08-04 | $124.64M 10-Q · filed 2022-08-04 | $177.02M derived: sum of 3 quarters · filed 2023-02-28 | $224.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $46.36M 10-Q · filed 2022-05-05 | $98.75M derived: sum of 2 quarters · filed 2023-02-28 | $145.78M derived: sum of 3 quarters · filed 2023-02-28 | $207.52M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $52.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $99.41M derived: sum of 2 quarters · filed 2023-02-28 | $161.15M derived: sum of 3 quarters · filed 2023-02-28 | $206.02M 10-K · filed 2023-02-28 |
| 2020-09-30 | $47.03M 10-Q · filed 2021-11-10 | $108.77M derived: sum of 2 quarters · filed 2021-11-10 | $153.64M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $61.74M 10-Q · filed 2021-08-12 | $106.61M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $44.87M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $183.60M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |